Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide, but effective treatments are still lacking. Metabolic disorders such as iron overload, glycolysis, insulin resistance, lipid dysregulation, and glutaminolysis are found to...
Saved in:
Main Authors: | Wei Xuan, Dandan Song, Jianghua Hou, Xiuping Meng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1505117/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression
by: Du Jiamin, et al.
Published: (2022-09-01) -
YAP/TAZ-associated cell signaling – at the crossroads of cancer and neurodevelopmental disorders
by: Aderonke O. Ajongbolo, et al.
Published: (2025-01-01) -
Exploring the Revolutionary Impact of YAP Pathways on Physical and Rehabilitation Medicine
by: Carmelo Pirri
Published: (2025-01-01) -
Transient activation of YAP/TAZ confers resistance to morusin-induced apoptosis
by: Hoyeon Lee, et al.
Published: (2025-01-01) -
Role of YAP/TAZ in bone diseases: A transductor from mechanics to biology
by: Xin Chen, et al.
Published: (2025-03-01)